InsiderTrades.com logo
Adam Dubow net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Adam Dubow Biography and Net Worth

General Counsel of Day One Biopharmaceuticals

Adam Dubow joined Day One as General Counsel in October 2022 following a 22-year tenure at Bristol Myers Squibb, where he most recently served as Chief Compliance and Ethics Officer, establishing a best-in-class global compliance program.

In addition to serving on the Bristol Myers Squibb’s management team, Adam previously served as the Company’s Lead Counsel for the Global Research and Development organization. Prior to this role, he directed the Legal Teams for the Europe, Middle East & Africa, as well as the Asia Pacific and Japan Regions. He also created and led the Global Corporate Policy function at Bristol Myers Squibb.

Prior to joining Bristol Myers Squibb, Adam was a Partner at Sedgwick, Detert, Moran & Arnold, where he specialized in products liability litigation. Adam currently serves on the Global Board of the Healthcare Businesswomen’s Association. He holds an undergraduate degree from Brandeis University, and a J.D. from Fordham University School of Law. Adam is a member of the New York State Bar.

What is Adam Dubow's net worth?

The estimated net worth of Adam Dubow is at least $247,512.50 as of February 18th, 2025. Mr. Dubow owns 39,602 shares of Day One Biopharmaceuticals stock worth more than $247,513 as of May 16th. This net worth evaluation does not reflect any other assets that Mr. Dubow may own. Learn More about Adam Dubow's net worth.

How old is Adam Dubow?

Mr. Dubow is currently 57 years old. There are 4 older executives and no younger executives at Day One Biopharmaceuticals. Learn More on Adam Dubow's age.

How do I contact Adam Dubow?

The corporate mailing address for Mr. Dubow and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at hans@lifesciadvisors.com. Learn More on Adam Dubow's contact information.

Has Adam Dubow been buying or selling shares of Day One Biopharmaceuticals?

Adam Dubow has not been actively trading shares of Day One Biopharmaceuticals during the last quarter. Most recently, Adam Dubow sold 4,646 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a transaction totalling $55,566.16. Following the completion of the sale, the general counsel now directly owns 39,602 shares of the company's stock, valued at $473,639.92. Learn More on Adam Dubow's trading history.

Who are Day One Biopharmaceuticals' active insiders?

Day One Biopharmaceuticals' insider roster includes Jeremy Bender (CEO), Samuel Blackman (Insider), Adam Dubow (General Counsel), Papanek Grant (Director), Saira Ramasastry (Director), and Charles York, II (Chief Operating and Financial Officer). Learn More on Day One Biopharmaceuticals' active insiders.

Are insiders buying or selling shares of Day One Biopharmaceuticals?

During the last twelve months, insiders at the sold shares 18 times. They sold a total of 167,625 shares worth more than $2,400,038.23. The most recent insider tranaction occured on February, 18th when CFO Charles N York II sold 4,370 shares worth more than $52,265.20. Insiders at Day One Biopharmaceuticals own 6.2% of the company. Learn More about insider trades at Day One Biopharmaceuticals.

Information on this page was last updated on 2/18/2025.

Adam Dubow Insider Trading History at Day One Biopharmaceuticals

See Full Table

Adam Dubow Buying and Selling Activity at Day One Biopharmaceuticals

This chart shows Adam Dubow's buying and selling at Day One Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$60k-$40k-$20k$0$20k$40k$60kTotal Insider BuyingTotal Insider Selling

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $6.25
Low: $6.08
High: $6.32

50 Day Range

MA: $7.49
Low: $6.16
High: $8.79

2 Week Range

Now: $6.25
Low: $6.08
High: $16.76

Volume

2,739,476 shs

Average Volume

1,099,809 shs

Market Capitalization

$633.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A